Reaction Details Report a problem with these data
Target
IgG receptor FcRn large subunit p51
Ligand
BDBM50270826
Substrate
n/a
Meas. Tech.
ChEMBL_552585 (CHEMBL956457)
pH
6±n/a
Kd
2000±n/a nM
Comments
extracted
Citation
 Mezo, AR; McDonnell, KA; Castro, A; Fraley, C Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem 16:6394-405 (2008) [PubMed]  Article 
Target
Name:
IgG receptor FcRn large subunit p51
Synonyms:
FCGRN_HUMAN | FCGRT | FCRN
Type:
PROTEIN
Mol. Mass.:
39742.86
Organism:
Homo sapiens (Human)
Description:
ChEMBL_627631
Residue:
365
Sequence:
MGVPRPQPWALGLLLFLLPGSLGAESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSSVLVVGIVIGVLLLTAAAVGGALLWRRMRSGLPAPWISLRGDDTGVLLPTPGEAQDADLKDVNVIPATA
  
Inhibitor
Name:
BDBM50270826
Synonyms:
CHEMBL511030
Type:
Small organic molecule
Emp. Form.:
C85H122N24O22S2
Mol. Mass.:
1896.156
SMILES:
CC(C)C[C@H](NC(=O)CNC(=O)CN(C)C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(C)(C)S)[C@@H](C)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O |r,wU:89.91,104.109,129.135,72.75,28.36,50.60,4.4,42.44,114.118,83.87,wD:61.71,17.25,46.48,108.112,(35.12,-24.18,;35.12,-25.72,;36.46,-26.49,;33.79,-26.49,;33.79,-28.03,;32.45,-28.8,;31.12,-28.03,;31.12,-26.48,;29.79,-28.8,;28.46,-28.03,;27.13,-28.81,;27.13,-30.34,;25.79,-28.04,;24.46,-28.8,;24.46,-30.34,;23.12,-28.04,;23.12,-26.49,;21.79,-28.81,;21.78,-30.34,;20.97,-31.65,;21.7,-33,;20.89,-34.31,;19.36,-34.27,;18.62,-32.91,;19.42,-31.6,;20.46,-28.04,;19.13,-28.82,;19.13,-30.36,;17.8,-28.05,;17.8,-26.5,;19.13,-25.74,;20.54,-26.37,;21.57,-25.22,;20.79,-23.89,;19.29,-24.21,;16.45,-28.8,;15.11,-28.04,;15.11,-26.49,;13.78,-28.81,;12.44,-28.03,;11.11,-28.81,;11.11,-30.34,;9.77,-28.03,;8.44,-28.8,;7.11,-28.03,;7.11,-26.49,;5.78,-28.81,;4.45,-28.04,;3.12,-28.82,;3.12,-30.36,;1.78,-28.05,;1.78,-26.5,;3.12,-25.74,;4.46,-26.51,;5.79,-25.74,;5.79,-24.19,;4.44,-23.43,;3.12,-24.21,;.44,-28.81,;-.89,-28.04,;-.89,-26.5,;-2.22,-28.81,;-2.22,-30.35,;-.89,-31.12,;-.89,-32.66,;.44,-33.42,;.46,-34.96,;-.89,-35.73,;1.78,-35.73,;-3.55,-28.03,;-4.86,-28.83,;-4.86,-30.37,;-6.19,-28.06,;-7.54,-28.8,;-6.19,-26.51,;-4.86,-25.75,;-4.86,-24.2,;-6.19,-23.44,;-3.52,-23.44,;5.78,-30.34,;7.32,-30.35,;4.23,-30.33,;5.78,-31.89,;9.77,-26.49,;8.45,-25.72,;11.11,-25.72,;35.12,-28.8,;35.12,-30.34,;36.46,-28.03,;37.78,-28.8,;39.12,-28.03,;39.12,-26.49,;37.79,-25.73,;37.79,-24.19,;39.12,-23.41,;39.12,-21.87,;40.46,-24.18,;40.47,-25.71,;37.78,-30.34,;36.46,-31.11,;39.12,-31.11,;40.69,-30.59,;41.72,-31.92,;40.77,-33.3,;39.37,-32.62,;38.14,-33.54,;36.72,-32.94,;38.12,-35.08,;36.78,-35.85,;35.46,-35.07,;34.11,-35.83,;36.77,-37.39,;38.09,-38.18,;35.42,-38.14,;35.41,-39.68,;36.74,-40.46,;36.72,-42,;35.38,-42.74,;38.05,-42.78,;34.07,-40.43,;32.74,-39.65,;34.05,-41.97,;32.71,-42.72,;32.7,-44.26,;34.03,-45.05,;31.36,-45.02,;31.03,-46.68,;29.37,-46.89,;28.66,-45.37,;29.94,-44.51,;29.76,-42.98,;28.33,-42.39,;30.98,-42.04,)|
Structure:
Search PDB for entries with ligand similarity: